Revenue beat, margins stumble—execution risk emerges
Supriya reported 31% YoY revenue growth but EBITDA margins compressed to 25% against guided 33–35%. Management blamed temporary water and power shocks totalling ₹10.5 Cr—but even excluding these, a 600–700 bps residual gap points to structural pressure.
₹189.7 Cr
+31% YoY
₹47 Cr
-8.1% YoY; 25% margin
₹24 Cr
-31% YoY; 12.5% margin
33–35%
Delivered: 25% (−800 bps)
The quarter landed with a paradox: Supriya's top line accelerated 31% YoY to ₹189.7 Cr, outpacing its 20% guidance baseline, yet profit fell 31% YoY to ₹24 Cr. The culprit is margin compression at scale. EBITDA margin landed at 25%, an 800 basis-point miss to the guided 33–35% range. Management pinned ₹10.5 Cr of this to external shocks—water scarcity at Lote and Maharashtra's solar subsidy policy change. But even after accounting for these headwinds, a 600–700 bps gap remains unexplained, signalling structural pressure beneath the growth story.
Margin miss: what holds up, what doesn't
EBITDA margins impacted by temporary water and power cost shocks totalling ₹10.5 Cr
OverstatedEBITDA ₹47 Cr on ₹189.7 Cr revenue = 24.7% margin. Even with ₹10.5 Cr benefit, margin reaches ~26%, still 700 bps short of 33–35% range
31% YoY revenue growth reflects strong demand
SupportedRevenue ₹189.7 Cr YoY +30.8%, corroborated. But QoQ −31.4% shows severe Q1 dip (water deferral of ₹35 Cr cited)
Excluding one-offs, margins would remain within guided range
ContradictedEven excluding ₹10.5 Cr external impact, residual margin ~26%, still 700 bps below guidance. New product ramps, CDMO strategy, and Ambernath depreciation (14–15 Cr annualized) driving structural compression
PAT margin at 12.7%
SupportedDelivered PAT ₹24 Cr / revenue ₹189.7 Cr = 12.6% margin
Water deferment of ₹35 Cr will be recovered in coming quarters
PartialDemand confirmed intact by mgmt; deferral was timing, not loss. Recovery claim plausible but not yet proven
The core issue is earnings quality. PAT fell 31% YoY despite revenue rising 31%—operating leverage has inverted. Ambernath's startup depreciation (14–15 Cr annualized) is one factor. But the deeper pressure is mix: new product launches (anesthetics, contrast media) and the CDMO strategy both start at lower margins as they scale. Management's own commentary acknowledges margins will stay at 33–35% 'for the next 3–4 years' due to CDMO-driven lower initial margins. That is not temporary; that is structural, and it was not front-and-centre in prior guidance.
What changed on this call
Q2 maintenance shutdown cancelled → phased debottlenecking instead
Ambernath two anesthetic products launched commercially; EU audit confirmed for November 2026
Margin guidance narrowed to 32–35% (from 33–35%)—subtle acknowledgment of floor risk
Inventory at ₹230–240 Cr (4.2x monthly revenue); phased liquidation planned over 3–4 quarters
Patalganga Phase-1 ground broken; 2.5-year ramp to 40% operational capacity (API blocks, advanced intermediates)
Street view: valuation, flows, and sentiment
The stock fell 2.69% on day 1 post-result, signalling the margin miss was not priced in. Now at ₹803.4, it sits 25.95% below its all-time high of ₹1,085 and trades below both its 20-day and 50-day moving averages (₹853.31 and ₹891.3, respectively), though above the 200-day SMA of ₹754.95. RSI at 39.6 suggests neutral footing, and volume is increasing—a mix of de-risking and potential accumulation. FII ownership ticked up 103 basis points QoQ to 6.19% (from 5.16% in Q4 FY26), suggesting foreign money is buying into the drawdown; DII flat to slightly negative. Promoter holding steady at 68.3%. The tape is saying: the margin miss is real, but the long-term story (CDMO, Patalganga, product launches) retains credibility.
31% YoY revenue growth outpacing 20% baseline; FY27 ₹1,000 Cr target remains feasible
Backward-integrated 72% of revenue (API + advanced intermediate); defensive moat vs. pure-API peers
Ambernath CMO/CDMO facility commercially live; EU audit November 2026 unlocks formulation ramps
FII inflows (+103 bps QoQ) suggest institutional confidence in long-term story
EBITDA margin compressed to 25% vs. 33–35% guided (−800 bps); residual gap 600–700 bps unexplained
PAT fell 31% YoY on 31% revenue growth—operating leverage inverted; Ambernath depreciation drag (14–15 Cr annualized)
Inventory ₹240 Cr (4.2x monthly revenue); phased liquidation over 3–4 quarters = working capital strain
Margin recovery to 33–35% is claimed but not yet proven; guidance narrowed to 32–35%
Customs compliance lapse (narcotics shipment, employee in judicial custody); regulatory cost rising
CDMO strategy caps margins at 33–35% for next 3–4 years per mgmt commentary—structural, not cyclical ceiling
Risks, ranked by how much they should concern a holder
Margin recovery unproven; structural compression vs. cyclical
HighEven excluding ₹10.5 Cr external shocks, margin gap is 600–700 bps. Product mix (new launches at lower ramp margins), CDMO strategy (lower-margin innovator deals), and Ambernath startup depreciation are structural, not temporary. If margins do not recover to 33–35% by H2 FY27, street revisions will be steep.
Inventory liquidation over 3–4 quarters = working capital drag + potential for discounting
High₹240 Cr inventory (4.2x monthly revenue) was built for a cancelled Q2 maintenance shutdown. Planned phased liquidation will tie up cash, constrain product mix flexibility, and may require discounts to accelerate offtake—eroding realized margins further.
Water scarcity recurrence; Lote facility depends on Koyna River monsoon variability
MediumQ1 ₹35 Cr revenue deferral due to delayed monsoon onset. Water recycling project is early-stage, not yet proven. Lote historically high-rainfall, but monsoon variability is structural to the region. Recurrence would again defer revenue and stress margins.
Power/fuel cost inflation; Maharashtra solar subsidy policy change is structural
MediumQ1 ₹8 Cr EBITDA impact from solar subsidy policy change. Backpay (₹4.5–5 Cr) is one-time, but forward increases are structural. Mgmt claims cost pass-through to customers on PO basis—but not guaranteed in competitive markets. Margin floor may stay depressed.
Customs/narcotics compliance lapse; precedent risk on export approvals
MediumOne psychotropic (narcotic) shipment lapsed due to human error (logistics GM in judicial custody). Matter sub judice. If CBN tightens precedent on export compliance, broader psychotropic shipment approvals could face delays or scrutiny—adding regulatory cost.
Patalganga Phase-1 capex (₹200 Cr over 2.5 years) execution risk; gate items (MIDC approval, GMP audits) may slip
MediumCapex is essential to unlock API capacity (Lote saturation) and CDMO upside. But 2.5-year ramp to 40% operational completion is aggressive. Regulatory approvals and GMP audits are gate items; delays would compress medium-term growth.
What to watch next
1 · Q2 EBITDA margin delivery (due in ~4–5 weeks post-quarter-end)
This is the pivot. If margins recover to 28–30% or higher as water/power normalize, the 'temporary shock' thesis holds. If they stay at 25–26%, structural pressure is real and upgrades stall. No need for full 33–35% yet, but the trend direction (recovery vs. continued compression) decides credibility.
2 · Inventory liquidation pace (watch cumulative reduction each quarter)
Mgmt committed to ₹240 Cr liquidation over 3–4 quarters. If Q2 shows less than ₹60 Cr reduction (normal pace), working capital risk is real and cash flow will stay tight. If ₹80+ Cr, mgmt is aggressive on de-stocking and confidence is rising.
3 · Ambernath EU audit outcome (November 2026)
CEP (anesthetic API) approval is expected post-audit. Clearance unlocks finished-formulation ramps with European customers, a structural margin upside beyond CMO/CDMO. Delay or findings would push upside into FY28 or later.
4 · CMO/CDMO term sheet announcement (expected Q2 FY27)
Mgmt flagged a major anesthetic CMO deal close pending in Q2. Scale, margin structure, and customer names will clarify CDMO upside and validate the strategy's return profile.
Supriya Lifescience is not in crisis, but it is in a fork. The company has proven 31% YoY revenue growth and built rare backward-integrated + CDMO capabilities in regulated pharma API space—real moats. But it is also managing down expectations on margins (33–35% to 32–35%), dealing with working capital strain (inventory at 4.2x monthly revenue), and facing structural headwinds (new products ramping at lower initial margins, CDMO strategy capping returns, Ambernath startup depreciation drag). Management's claim that Q1 margin miss was 'largely temporary' does not square with the numbers; even adjusting for externals, a 600–700 bps residual gap points to mix and execution friction.
The honest read: execution risk is real in the near term; the long-term story (CDMO, Patalganga, innovator partnerships) retains credibility if executed. This is not a 'best of breed pharma API' story anymore—it's a 'restructuring into CDMO with margin discipline' story. The debate resolves in Q2–Q3 when margin recovery is either proven or further missed. Until then, hold rather than buy. The single number to track from here is Q2 EBITDA margin. Above 28% and the quarter was an anomaly; below 27% and structural pressure is the narrative.
Strong revenue, margin miss signals execution risk
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Guided 33-35% EBITDA margins but delivered 25%. Water and power headwinds are cited but do not fully explain the 800 bps gap. Reaffirmed FY27 targets despite Q1 miss.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 revenue growth of 31% YoY is robust and supports the FY27 1,000 Cr trajectory. However, EBITDA margins compressed to 25% vs. 33-35% guidance, and PAT fell 31% YoY despite strong top-line growth. Management attributes the miss to temporary water scarcity and power policy shocks (₹10.5 Cr impact), but structural margin compression remains evident. Execution risk is real; margin recovery must be proven in H2.
₹189.7 Cr
Revenue · +30.8% YoY₹24 Cr
Reported PAT · −30.9% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
EBITDA margins impacted by temporary water and power cost shocks totalling ₹10.5 Cr
OVERSTATEDEBITDA 47 Cr on 189.7 Cr revenue = 24.7% margin, 800-1000 bps below 33-35% guidance
31% YoY revenue growth reflects strong demand
METRevenue 189.7 Cr YoY +30.8%, corroborated; but QoQ -31.4% shows severe Q1 dip
Excluding one-offs, margins would remain within guided range
MISSEven with 10.5 Cr benefit, EBITDA margin reaches only ~26.2%, still 700 bps below 33-35%
PAT margins at 12.7%
METDelivered PAT margin 12.5%, minor rounding variance
Water deferment of ₹35 Cr will be recovered in coming quarters
PartialDemand confirmed strong; deferral was timing, not loss. Recovery claim plausible but not yet proven
Earnings quality
What changed since the last call
Margin guidance narrowed to 32-35%
DowngradePrior: 33-35%. New: 32-35% (one instance). Implies floor acknowledgment. Q1 at 25% signals full-year recovery path is steep.
Q2 maintenance shutdown cancelled
UpgradeOriginally planned big August shutdown across blocks A-D scrapped; phased debottlenecking instead. Protects Q2 production given Q1 loss.
Ambernath capex pace accelerated
UpgradeAlready launched two anesthetic products Q2. EU audit moved to Nov 2026 (confirmed vs prior ambiguity). Finished formulation ramp to follow audit clearance.
Inventory at 240 Cr vs normal ~80-100 Cr
DowngradePlanned maintenance build now being liquidated over 3-4 qtrs. Working capital drag confirmed, product mix flexibility constrained near-term.
The Q&A
Analysts pressed hard on margin miss (Nikhil, Mulesh, Rachna); mgmt held firm on temporary shock narrative but offered limited forward margin visibility beyond 'Q2 will be better.' Customs issue faced skepticism; mgmt clarified it was one-time human error on a psychotropic product. Overall Q&A was rigorous; mgmt tone shifted from confident (opening) to defensive (margins, customs) but did not dodge.
Margin compression drivers — Nikhil, SIMPL
AnsweredSolar subsidy: govt collecting ₹4.5-5 Cr backpay (Mar-Jul) as one-time; future increases will be passed to customers on PO basis. Water resolved by late monsoon onset.
Patalganga timeline risk — Adityapal, MSA Capital
PartialGround broken; boundary walls underway in Isambe. API block first (2.5 yr to 40% completion per MIDC rule). Formulation phase-2 later. No near-term bottleneck.
Customs/narcotics issue severity — Mulesh, Shah and Savla
AnsweredEach psychotropic consignment needs unique CBN export auth. Lapse was one shipment only; new auth received; matter sub judice. Non-recurrence via SAP implementation planned.
DSM ramp and supply confidence — Nirmam, Unique PMS
AnsweredDSM very stable, near peak volumes. Pharma validation done; dedicated facility operational. Traction very positive.
Revenue mix and EBITDA drivers — Rachna, SIMPL
PartialMix impact + Europe sales lower + production losses = multiple factors. Backward integration at 72%; mix shift was seasonal/temporary.
CMO-CDMO opportunity scale — Tushar, MK Ventures
PartialOpportunity is large; SAP live in 4-5 months; R&D team 20-30 to 70; automization ongoing. Potential to grow beyond 20% if regulatory approvals fast.
FY28 guidance — Saloni Singh, investor
Answered20% CAGR baseline. Beyond FY27: multiple verticals (CMO, finished formulation, capacity), no specific FY28 number. Growth >20% possible.
Cash and capex plans — Mithin Shah, investor
AnsweredCash 150 Cr FDs/MF. Phase-1 200 Cr (API + utility blocks). Phase-2 similar or larger. First 40% completion ~2.5 years from now.
Guidance
FY27: closer to ₹1,000 Cr (20% YoY growth CAGR baseline)
HighQ1 revenue 189.7 Cr implies ~270 Cr/qtr needed; Q1 was 31% YoY growth. Non-linear due to product ramps, water loss recovery
EBITDA margins: 32% to 35% (narrowed from 33-35% in prior calls)
MediumQ1 at 25% signals recovery path is steep. Mgmt claims temporary shocks; claims to pass cost inflation to customers on PO basis
Margins remain 33-35% through next 3-4 years due to CMO/CDMO ramps + new product scaling at lower margins initially
MediumStructural margin cap acknowledged by mgmt; finished formulation and CDMO projects slower to scale than API
Patalganga Phase-1: ₹200 Cr for API blocks, advanced intermediate blocks, utility infrastructure (2.5 yr ramp to 40%)
HighApproved by MIDC; ground broken; boundary wall construction underway. First focus on API capacity (Lote approaching saturation)
Block F Lote expansion: start in next couple of quarters
MediumSmaller debottlenecking vs Patalganga; timeline after annual maintenance phased approach
Risks the call surfaced
Operational — water scarcity
MediumLote facility depends on Koyna River; monsoon delayed Q1, causing ₹35 Cr deferral. Water recycling project in early stages; not yet mitigated.
Cost inflation — power/fuel
MediumMaharashtra solar subsidy policy change Jan 2026 caused ₹8 Cr EBITDA impact Q1. ToD rate reduction adds structural cost. Backpay (₹4.5-5 Cr) is one-time; forward increases ongoing.
Compliance — narcotics shipment
MediumOne psychotropic (narcotic) product consignment shipped with expired export authorization due to 2-day human error by logistics dept (GM). Shipping bill under investigation. Matter sub judice. Mgmt claims 'miniscule value' but risk to broader export approvals if precedent tightened.
Financial — inventory buildup & liquidation
MediumClosing inventory at ₹230-240 Cr (4.2x monthly revenue ~57 Cr). Planned for Aug Q2 maintenance shutdown now cancelled; phased debottlenecking instead. Mgmt to liquidate over 3-4 quarters. High inventory constrains cash & product mix flexibility.
Execution — margin recovery unproven
HighQ1 EBITDA margin 25% vs 33-35% guidance is 800-1000 bps miss. Mgmt cites ₹10.5 Cr external shocks, but even with benefit, margin ~26-27%, still 600-700 bps short. Mix shifts (product ramps at lower initial margins, CDMO lower-margin projects), manufacturing inefficiencies, and competitive pressures not fully disclosed.
Management
Score 6/10. Transparent on water/power headwinds and customs lapse; defensive on margin miss (blamed externals but residual gap unexplained). Provided detailed timelines (Ambernath EU audit Nov, Patalganga 2.5-yr ramp, R&D expansion 20-30 to 70). Acknowledged growth non-linearity. Evasive on FY28 guidance and specific margin recovery pathway. Hit 31% YoY revenue growth (above 20% guidance). Missed 33-35% EBITDA margin target significantly (delivered 25%). Brought Ambernath to commercial launch stage (two anesthetics). DSM fully ramped and stable. Patalganga ground broken but capex still in early phase. Track record: revenue guidance tracking; margin guidance materially missed in Q1.
1 · Oct-Nov 2026
Ambernath EU audit; CEP approval expected Oct-Nov (anesthetic API)
2 · Q2 FY27
Margin recovery from power/water normalization; inventory liquidation begins
3 · H2 FY27
Contrast media launch (H2 FY27); CMO/CDMO term sheet announcement expected Q2
Execution risk is real; margin recovery must be proven in H2.
Supriya Lifescience Q1FY27: PAT down 31% YoY on margin squeeze despite 31% revenue growth
PAT -30.89% YoY · revenue +30.79% · margins compressing · miss vs street
₹189.75 Cr
+30.79% YoY
₹24.04 Cr
-30.89% YoY
12.5%
-11.1pp YoY
₹2.99
Supriya Lifescience's standalone Q1 FY27 (quarter ended June 30, 2026) revenue rose 30.8% YoY to ₹189.7 Cr (from ₹145.1 Cr), but standalone PAT fell 30.9% YoY to ₹24.0 Cr (from ₹34.8 Cr) — a classic case of top-line growth masking a sharp margin squeeze. Sequentially the picture is starker: revenue was down 31.4% and PAT down 67.6% versus the seasonally strong Q4 FY26 (₹276.5 Cr revenue, ₹74.2 Cr PAT), though Q4-to-Q1 sequential drops are typical for this business given its export-driven, lumpy order pattern. EPS came in at ₹2.99 versus ₹9.22 in Q4 FY26 and ₹4.32 a year ago.
Q1 FY-2027 vs prior quarters
The compression sits squarely on the cost line. Cost of materials consumed jumped to 57.7% of revenue (from ~30% both YoY and QoQ), and even after netting off a large finished-goods inventory build, net material cost intensity still rose to 29.7% of sales from 21.9% a year ago. Other expenditure also crept up to 30.3% of revenue from 26.8% YoY. Total expenses absorbed 79.9% of revenue versus 69.2% a year ago, pulling operating margin (PBT + depreciation + finance cost, over revenue) down to 25.0% from 35.6% YoY and 35.3% QoQ — well below management's own FY27 guidance band of 33-35% EBITDA margin. Net profit margin fell to 12.7% from 23.6% YoY and 26.5% QoQ.
The stock went into the print at ₹813.5, down 5.2% over the past month of trading.
What the summary numbers don't show
Standalone-only result — company confirms it has no subsidiary/associate/JV as of June 30, 2026, so no consolidated figures exist
Supriya Lifescience provided strong guidance for FY27, targeting INR1,000 crores in revenue, indicating an approximate 20% annual revenue growth and maintaining EBITDA margins between 33% and 35%. The company plans to further strengthen its product portfolio with approximately two new launches in the anesthetics and AD
— This quarter: missed
On guidance, management had targeted ~20% annual FY27 revenue growth toward a ₹1,000 Cr full-year target with 33-35% EBITDA margins; this quarter's 30.8% YoY revenue growth runs ahead of that pace, but the margin miss means the quarter reads as missing the guided profitability band even as topline outpaces it. Against Street, a pre-result trailing-growth model (Univest) had pencilled in a YoY decline — revenue ~₹131 Cr and PAT ~₹27 Cr — so the actual revenue print is a sizeable beat, but PAT of ₹24.0 Cr still came in below that ₹27 Cr estimate, a modest miss on the bottom line. No management press release was available to cross-check the company's own framing of the quarter. Separately, note 3 to the results discloses that export goods were intercepted and held in Customs custody as of quarter-end yet already recognised as a sale since the shipment had reached Customs for export processing — a disclosure that lines up with the company's July 2026 announcement that a General Manager was arrested by Customs and remains in judicial custody, a live overhang investors should track alongside the margin trajectory.
W1
Whether operating margin recovers toward management's guided 33-35% EBITDA band in Q2 FY27 as raw-material cost intensity (57.7% of revenue this quarter) eases
W2
Resolution of the Customs matter — GM in judicial custody and goods detained at quarter-end — and any effect on future export revenue recognition or logistics
W3
Pace toward the ₹1,000 Cr FY27 revenue target: Q1 delivered ₹189.7 Cr, requiring roughly ₹810 Cr across the remaining three quarters
No consolidated statement — company confirms (note 4) it has no subsidiary/associate/JV. Source unit ₹ Million, converted to Crore. No exceptional items this quarter (nil vs a negligible ₹0.46 Cr in FY26 full year), so no adjusted-YoY calc needed. Note 3: export goods intercepted/detained by Customs as of Jun 30, 2026 were still recognised as sale — ties to the Jul 2026 disclosure that a company GM was arrested by Customs and remains in judicial custody.